customer service software

PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition

  • Published Date: 19 Dec 2018
  • Number of Pages: 52
  • Category: Pharmaceuticals
  • Country: Global
PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition


This report is the 2nd edition of our analysis of Mergers and Acquisitions in the contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.


- Helps bio/pharmaceutical manufacturing, development, and supply chain executives understand the implications of M&A activity on their supply base and sourcing options.
- Helps executives at CMOs and associated contract services companies and investors to recognize the significance of M&A activities for the competitive dynamics of the industry and how company strategies must change to address the altering market.
- To gain insights that might enable predictions of the nature and implications of M&A activity in the next three to five years.

Reasons to buy

This 52-page report gives important, expert insight you wont find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for -
- CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
- Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking.
Publisher Name : GlobalData

1. Executive Summary 4
2 Objectives and Methodology 5
3 Overview of M&A Activity 2015-2017 6
Target Characteristics 7
Acquirer Characteristics 11
4 Segment Close-Ups of M&A Activity, 2015-2017 15
Dose Manufacturing 15
API - Biologic 18
API - Small Molecule 19
Analytical Services 21
Formulation and Clinical Supplies Manufacturing 24
Packaging 26
5 Valuations 27
6 Facility Acquisitions 29
7 What It Means 36
8 The Outlook for M&A in the Manufacturing Services Industry 39
9 Notes on Methodology 41
10 Appendix 42
Service Acquisitions 2015-2017 42
Bibliography 49
Primary Research - Key Opinion Leaders Cited in this Report 49
About the Authors 50

List Of Tables

Table 1: CMO Services Businesses Acquired as Part of Larger Deals, 2017 6
Table 2: Company Acquisitions by Target Service and Size, 2015-2017 9
Table 3: Company Acquisitions by Target Service and Ownership, 2015-2017 9
Table 4: Company Acquisitions by Target Market Scope and Size, 2015-2017 10
Table 5: Most Active Acquirers, 2015-2017 13
Table 6: Company Acquisitions of Dose Manufacturers, 2015-2017 16
Table 7: Company Acquisitions of API - Biologic Manufacturers, 2015-2017 19
Table 8: Company Acquisitions of API - Small Molecule Manufacturers, 2015-2017 20
Table 9: Company Acquisitions of Analytical Services, 2015-2017 22
Table 10: Company Acquisitions of Formulation Manufacturers, 2015-2017 25
Table 11: Company Acquisitions of Contract Packagers, 2015-2017 26
Table 12: Services Deals with Known Transaction Value and Multiples, 2015-2017 27
Table 13: Facility Acquisitions by CMOs, 2015-2017 33
Table 14: Most Active Acquirers, 2015-2017 36
Table 15: Acquisitions by PE Firms, 2015-2017 37
Table 16: Potential Targets: API - Biologic (Non-Cell and Gene Therapy) Service Providers 39
Table 17: Potential Targets: API - Biologic (Gene and Cell Therapy Only) Service Providers 40
Table 18: Service Acquisitions, 2015-2017 42

List Of Figures

Figure 1: Company Acquisitions by Target Service Offering, 2015-2017 7
Figure 2: Company Acquisitions by Target Revenues, 2015-2017 8
Figure 3: Company Acquisitions by Target Ownership, 2015-2017 8
Figure 4: Acquisition Targets by Sophistication of Capabilities 11
Figure 5: Number of Acquisitions by Acquirers Core Business 12
Figure 6: Number of Acquisitions by Acquirer Ownership 13
Figure 7: Number of Acquisitions by Principal Acquirer Motivation 14
Figure 8: Dose Forms Manufactured by Acquired Dose Manufacturers 15
Figure 9: Pharma CMO Facility Acquisitions, 2015-2017 30

PharmSource - Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars - 2018 Edition Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large

View Report

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2018 Edition The motivation for pharma companies outsourcing their manufacturing is often to do with

View Report

PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition This PharmSource Trend Report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports